Next-Gen Antisense and Small Protein-Protein Disruptors Benefit SOD1 Models
Oligonucleotides that suppress SOD1, and small molecules that limit its binding to the protein Derlin-1, delay disease onset and extend lifespan in rodent models of ALS.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
$30 Million Venture Philanthropy Project for AD Biomarkers
Investors pledge new money for research into biomarkers that yield marketable tests.
Alzheimer's Association International Conference 2018
BAN2401 Removes Brain Amyloid, Possibly Slows Cognitive Decline On Target: Crenezumab Reduces Aβ Oligomers in CSF PET Ligand Lights Up AAIC, May Detect Synapse Loss in AD Could Better Blood Pressure Management Preserve Cognition? Focused Ultrasound Breach
Could Better Blood Pressure Management Preserve Cognition?
In SPRINT MIND trial, strict control of systolic pressure slashed MCI incidence by almost 20 percent.
No Mutation Required? Cell Stress Goads Aggregation of Wild-Type SOD1
In mice, aggregates of oxidized SOD1 accumulated with age, and endoplasmic reticulum stress made it worse. Does this explain SOD1 aggregates found in spinal cords of patients with sporadic ALS?
Focused Ultrasound Breaches Blood-Brain Barrier in People with Alzheimer’s
Data from the first human study hints the procedure could help deliver drugs to the brain, or even work as a therapy in its own right. A flurry of animal studies presented at AAIC support the idea.
Donepezil Not the Answer for Depressed MCI Patients
The acetylcholinesterase inhibitor failed to slow cognitive decline in people with both depression and mild cognitive impairment.
FDA Approves First RNAi Therapy
The drug, patisiran, targets messenger RNAs that cause transthyretin amyloidosis, a rare inherited neurodegenerative disease. Approval paves the way for other RNAi-based therapies.
Largest AD Whole-Exome Study to Date Finds Two New Risk Genes
A zinc-finger protein and a long noncoding RNA are now implicated in late-onset Alzheimer’s disease.
Memory Slips as Soon as Amyloid Appears, Two Decades Before Dementia
Sensitive cognitive tests detect deficits in preclinical Alzheimer’s even before an amyloid scan reads positive. And CSF Aβ42 drops a decade before that—pushing research ever farther into the preclinical phase.
With Sudden Progress, Blood Aβ Rivals PET at Detecting Amyloid
At AAIC, competitors vied for advantage, and discussion moved swiftly to the issue of assay standardization.
Weeklong Chinese Challenge Reveals Subtle Memory Problems
At AAIC, technology improves on pen-and-paper tests of early cognitive decline. Think learning Chinese, think smartphone burst, think digital clock.
Do Brain Changes at Menopause Make Women More Prone to Alzheimer’s?
At AAIC, scientists said that alterations in how the aging female brain uses energy and metabolizes fat may leave APOE4 carriers particularly susceptible to tau pathology.
Estrogen’s Benefit Tied to Age: Good for the Young, Bad for the Old
Greater lifetime estrogen exposure protects cognition, while hormone replacement therapy taken at menopause has no cognitive effects at all.
Brain Damage from Cardiovascular Disease Starts Earlier Than You Think
Data from two independent cohorts suggest that the risk to the brain from high blood pressure and cardiovascular disease begins in a person’s 40s or before.
Current Filters
No filters selected